Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
6/3/2026, 12:00:00 AM
The New Drug Application (NDA) for Olipudase (奥莱泊肽), a GLP-1/GIP dual receptor agonist, was accepted for review by China's NMPA on June 3, 2026. Analysts estimate a >10% price impact due to the drug's significant market potential expected.
Korean Translation
GLP-1/GIP 이중 수용체 작용제인 올레포타이드(奥莱泊肽)의 신약 허가 신청(NDA)이 2026년 6월 3일 중국 NMPA에 접수될 것으로 예상됨. 분석가들은 해당 약물의 시장 잠재력에 따른 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Pacific Biosciences of California Inc (PACB) · Earnings Release
Q2 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM
Jinxin Fertility Group Limited (1951) · Other
Ex-dividend date on 2026-06-29 for the 2025 final dividend of HK$0.0418 per share; Low importance justified by it being a standard technical adjustment scheduled
6/29/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Jinxin Fertility Group Limited (1951) · Other
Annual General Meeting on 2026-06-25 to vote on 2025 financial statements and a HK$0.0418 dividend; Low importance justified by the routine nature of the meeting scheduled
6/25/2026, 12:00:00 AM
Biocytogen Pharmaceuticals (Beijing) Co Ltd (2315) · Other
An extraordinary general meeting is scheduled on 2026-06-25 to vote on a new executive remuneration system and a 10% H-share repurchase mandate; 1% price impact expected.
6/25/2026, 12:00:00 AM